SLC5A2 and atrial fibrillation: Our meta-analysis of 39 RCTs demonstrated that patients treated with SGLT2 inhibitors had a significantly lower risk of AF/AFL compared with those receiving placebo (RR 0.86; 95%CI, 0.77–0.95; P = 0.003).